Skip to main content
Top
Published in: Diagnostic Pathology 1/2017

Open Access 01-12-2017 | Research

Gene expression profiling in uveal melanoma: technical reliability and correlation of molecular class with pathologic characteristics

Authors: Kristen M. Plasseraud, Jeff K. Wilkinson, Kristen M. Oelschlager, Trisha M. Poteet, Robert W. Cook, John F. Stone, Federico A. Monzon

Published in: Diagnostic Pathology | Issue 1/2017

Login to get access

Abstract

Background

A 15-gene expression profile test has been clinically validated and is widely utilized in newly diagnosed uveal melanoma (UM) patients to assess metastatic potential of the tumor. As most patients are treated with eye-sparing radiotherapy, there is limited tumor tissue available for testing, and technical reliability and success of prognostic testing are critical. This study assessed the analytical performance of the 15-gene expression test for UM and the correlation of molecular class with pathologic characteristics.

Methods

Inter-assay, intra-assay, inter-instrument/operator, and inter-site experiments were conducted, and concordance of the 15-gene expression profile test results and associated discriminant scores for matched tumor samples were evaluated. Technical success was determined from de-identified clinical reports from January 2010 - May 2016. Pathologic characteristics of enucleated tumors were correlated with molecular class results.

Results

Inter-assay concordance on 16 samples run on 3 consecutive days was 100%, and matched discriminant scores were strongly correlated (R2 = 0.9944). Inter-assay concordance of 46 samples assayed within a one year period was 100%, with an R2 value of 0.9747 for the discriminant scores. Intra-assay concordance of 12 samples run concurrently in duplicates was 100%; discriminant score correlation yielded an R2 of 0.9934. Concordance between two sites assessing the same tumors was 100% with an R2 of 0.9818 between discriminant scores. Inter-operator/instrument concordance was 96% for Class 1/2 calls and 90% for Class 1A/1B calls, and the discriminant scores had a correlation R2 of 0.9636. Technical success was 96.3% on 5516 samples tested since 2010. Increased largest basal diameter and thickness were significantly associated with Class 1B and Class 2 vs. Class 1A signatures.

Conclusions

These results show that the 15-gene expression profile test for UM has robust, reproducible performance characteristics. The technical success rate during clinical testing remains as high as first reported during validation. As molecular testing becomes more prevalent for supporting precision medicine efforts, high technical success and reliability are key characteristics when testing such limited and precious samples. The performance of the 15-gene expression profile test in this study should provide confidence to physicians who use the test’s molecular classification to inform patient management decisions.
Appendix
Available only for authorised users
Literature
1.
go back to reference Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110(5):956–61.CrossRefPubMed Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110(5):956–61.CrossRefPubMed
2.
go back to reference Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report no. 28. Arch Ophthalmol. 2006;124(12):1684–93. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report no. 28. Arch Ophthalmol. 2006;124(12):1684–93.
3.
go back to reference Kivela T, Kujala E. Prognostication in eye cancer: the latest tumor, node, metastasis classification and beyond. Eye (Lond). 2013;27(2):243–52.CrossRef Kivela T, Kujala E. Prognostication in eye cancer: the latest tumor, node, metastasis classification and beyond. Eye (Lond). 2013;27(2):243–52.CrossRef
4.
go back to reference Kujala E, et al. Staging of ciliary body and choroidal melanomas based on anatomic extent. J Clin Oncol. 2013;31(22):2825–31.CrossRefPubMed Kujala E, et al. Staging of ciliary body and choroidal melanomas based on anatomic extent. J Clin Oncol. 2013;31(22):2825–31.CrossRefPubMed
5.
go back to reference Diener-West M, et al. Screening for metastasis from choroidal melanoma: the collaborative ocular melanoma study group report 23. J Clin Oncol. 2004;22(12):2438–44.CrossRefPubMed Diener-West M, et al. Screening for metastasis from choroidal melanoma: the collaborative ocular melanoma study group report 23. J Clin Oncol. 2004;22(12):2438–44.CrossRefPubMed
6.
go back to reference Eskelin S, et al. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology. 2000;107(8):1443–9.CrossRefPubMed Eskelin S, et al. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology. 2000;107(8):1443–9.CrossRefPubMed
7.
go back to reference Onken MD, et al. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64(20):7205–9.CrossRefPubMedPubMedCentral Onken MD, et al. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64(20):7205–9.CrossRefPubMedPubMedCentral
8.
go back to reference Onken MD, et al. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn. 2010;12(4):461–8.CrossRefPubMedPubMedCentral Onken MD, et al. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn. 2010;12(4):461–8.CrossRefPubMedPubMedCentral
9.
go back to reference Onken MD, et al. Collaborative ocular oncology group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119(8):1596–603.CrossRefPubMedPubMedCentral Onken MD, et al. Collaborative ocular oncology group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119(8):1596–603.CrossRefPubMedPubMedCentral
10.
11.
go back to reference Febbo PG, et al. NCCN task force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Cancer Netw. 2011;9(Suppl 5):S1–32. quiz S33CrossRef Febbo PG, et al. NCCN task force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Cancer Netw. 2011;9(Suppl 5):S1–32. quiz S33CrossRef
12.
go back to reference Walsh PS, et al. Analytical performance verification of a molecular diagnostic for cytology-indeterminate thyroid nodules. J Clin Endocrinol Metab. 2012;97(12):E2297–306.CrossRefPubMed Walsh PS, et al. Analytical performance verification of a molecular diagnostic for cytology-indeterminate thyroid nodules. J Clin Endocrinol Metab. 2012;97(12):E2297–306.CrossRefPubMed
14.
go back to reference Vachani A, et al. Clinical utility of a bronchial genomic classifier in patients with suspected lung cancer. Chest. 2016;150(1):210–8.CrossRefPubMed Vachani A, et al. Clinical utility of a bronchial genomic classifier in patients with suspected lung cancer. Chest. 2016;150(1):210–8.CrossRefPubMed
16.
go back to reference Duick DS, et al. The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology. Thyroid. 2012;22(10):996–1001.CrossRefPubMedPubMedCentral Duick DS, et al. The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology. Thyroid. 2012;22(10):996–1001.CrossRefPubMedPubMedCentral
17.
go back to reference Alexander EK, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012;367(8):705–15.CrossRefPubMed Alexander EK, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012;367(8):705–15.CrossRefPubMed
18.
19.
go back to reference Correa ZM, Augsburger JJ. Sufficiency of FNAB aspirates of posterior uveal melanoma for cytologic versus GEP classification in 159 patients, and relative prognostic significance of these classifications. Graefes Arch Clin Exp Ophthalmol. 2014;252(1):131–5.CrossRefPubMed Correa ZM, Augsburger JJ. Sufficiency of FNAB aspirates of posterior uveal melanoma for cytologic versus GEP classification in 159 patients, and relative prognostic significance of these classifications. Graefes Arch Clin Exp Ophthalmol. 2014;252(1):131–5.CrossRefPubMed
20.
go back to reference Correa ZM, Augsburger JJ. Independent prognostic significance of gene expression profile class and largest basal diameter of posterior Uveal melanomas. Am J Ophthalmol. 2016;162:20–7. e1CrossRefPubMed Correa ZM, Augsburger JJ. Independent prognostic significance of gene expression profile class and largest basal diameter of posterior Uveal melanomas. Am J Ophthalmol. 2016;162:20–7. e1CrossRefPubMed
21.
go back to reference Demirci H, Ozkurt ZG, Slimani N, Cook R, Oelschlager K. Gene expression profiling test of uveal melanoma: prognostic validation. Las Vegas: American Society of Ophthalmic Plastic & Reconstructive Surgery Fall Scientific Symposium; 2015. Demirci H, Ozkurt ZG, Slimani N, Cook R, Oelschlager K. Gene expression profiling test of uveal melanoma: prognostic validation. Las Vegas: American Society of Ophthalmic Plastic & Reconstructive Surgery Fall Scientific Symposium; 2015.
22.
go back to reference Walter SD, et al. Prognostic implications of tumor diameter in association with gene expression profile for Uveal melanoma. JAMA Ophthalmol. 2016;134(7):734–40.CrossRefPubMedPubMedCentral Walter SD, et al. Prognostic implications of tumor diameter in association with gene expression profile for Uveal melanoma. JAMA Ophthalmol. 2016;134(7):734–40.CrossRefPubMedPubMedCentral
23.
go back to reference Plasseraud KM, et al. Clinical performance and management outcomes with the DecisionDx-UM gene expression profile test in a prospective multicenter study. Journal of Oncology. 2016;2016:1–9.CrossRef Plasseraud KM, et al. Clinical performance and management outcomes with the DecisionDx-UM gene expression profile test in a prospective multicenter study. Journal of Oncology. 2016;2016:1–9.CrossRef
24.
go back to reference Aaberg TM Jr, et al. Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses. Clin Ophthalmol. 2014;8:2449–60.CrossRefPubMedPubMedCentral Aaberg TM Jr, et al. Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses. Clin Ophthalmol. 2014;8:2449–60.CrossRefPubMedPubMedCentral
25.
go back to reference Harbour JW. A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile. Methods Mol Biol. 2014;1102:427–40.CrossRefPubMedPubMedCentral Harbour JW. A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile. Methods Mol Biol. 2014;1102:427–40.CrossRefPubMedPubMedCentral
26.
go back to reference Office for Human Research Protections. 45 Code of Federal Regulations Part 46 (45 CFR 6). Department of Health and Human Services; 2009. Office for Human Research Protections. 45 Code of Federal Regulations Part 46 (45 CFR 6). Department of Health and Human Services; 2009.
27.
go back to reference Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101(21):1446–52.CrossRefPubMedPubMedCentral Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101(21):1446–52.CrossRefPubMedPubMedCentral
28.
go back to reference Kivela, T., et al., Uveal Melanoma, in American Joint Committee on Cancer (AJCC) Staging Manual, M.B. Amin, Edge, M.B., Greene, F.L., Byrd, D.R., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R., Sullivan, D.C., Jessup, J.M., Brierley, J.D., Gaspar, L.E., Schilsky, R.L., Balch, C.M., Winchester, D.P., Asare, E.A., Madera, M., Gress, D.M., Meyer, L.R., Editor. 2017, Spring. Kivela, T., et al., Uveal Melanoma, in American Joint Committee on Cancer (AJCC) Staging Manual, M.B. Amin, Edge, M.B., Greene, F.L., Byrd, D.R., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R., Sullivan, D.C., Jessup, J.M., Brierley, J.D., Gaspar, L.E., Schilsky, R.L., Balch, C.M., Winchester, D.P., Asare, E.A., Madera, M., Gress, D.M., Meyer, L.R., Editor. 2017, Spring.
29.
go back to reference Onken MD, et al. Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. Clin Cancer Res. 2007;13(10):2923–7.CrossRefPubMed Onken MD, et al. Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. Clin Cancer Res. 2007;13(10):2923–7.CrossRefPubMed
30.
go back to reference Worley LA, et al. Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Cancer Res. 2007;13(5):1466–71.CrossRefPubMed Worley LA, et al. Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Cancer Res. 2007;13(5):1466–71.CrossRefPubMed
31.
go back to reference Midena E, et al. In vivo detection of monosomy 3 in eyes with medium-sized uveal melanoma using transscleral fine needle aspiration biopsy. Eur J Ophthalmol. 2006;16(3):422–5.PubMed Midena E, et al. In vivo detection of monosomy 3 in eyes with medium-sized uveal melanoma using transscleral fine needle aspiration biopsy. Eur J Ophthalmol. 2006;16(3):422–5.PubMed
32.
go back to reference Young TA, et al. Fluorescent in situ hybridization for monosomy 3 via 30-gauge fine-needle aspiration biopsy of choroidal melanoma in vivo. Ophthalmology. 2007;114(1):142–6.CrossRefPubMed Young TA, et al. Fluorescent in situ hybridization for monosomy 3 via 30-gauge fine-needle aspiration biopsy of choroidal melanoma in vivo. Ophthalmology. 2007;114(1):142–6.CrossRefPubMed
33.
go back to reference Shields CL, et al. Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases. Trans Am Ophthalmol Soc. 2007;105:43–52. discussion 52-3PubMedPubMedCentral Shields CL, et al. Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases. Trans Am Ophthalmol Soc. 2007;105:43–52. discussion 52-3PubMedPubMedCentral
34.
go back to reference Desjardins L, et al. FNA biopsies for genomic analysis and adjuvant therapy for uveal melanoma. Acta Ophthalmol. 2010;88:0. Desjardins L, et al. FNA biopsies for genomic analysis and adjuvant therapy for uveal melanoma. Acta Ophthalmol. 2010;88:0.
35.
go back to reference Schefler A, et al. Ocular Oncology Study Consortium (OOSC) Report No. 2: Effect of Clinical and Pathologic Variables on Biopsy Complication Rates. San Francisco: American Association of Retina Specialists; 2016. Schefler A, et al. Ocular Oncology Study Consortium (OOSC) Report No. 2: Effect of Clinical and Pathologic Variables on Biopsy Complication Rates. San Francisco: American Association of Retina Specialists; 2016.
36.
go back to reference Augsburger JJ, et al. Accuracy of clinical estimates of tumor dimensions. A clinical-pathologic correlation study of posterior uveal melanomas. Retina. 1985;5(1):26–9.CrossRefPubMed Augsburger JJ, et al. Accuracy of clinical estimates of tumor dimensions. A clinical-pathologic correlation study of posterior uveal melanomas. Retina. 1985;5(1):26–9.CrossRefPubMed
37.
go back to reference Decatur CL, et al. Driver mutations in Uveal melanoma: associations with gene expression profile and patient outcomes. JAMA Ophthalmol. 2016;134(7):728–33.CrossRefPubMedPubMedCentral Decatur CL, et al. Driver mutations in Uveal melanoma: associations with gene expression profile and patient outcomes. JAMA Ophthalmol. 2016;134(7):728–33.CrossRefPubMedPubMedCentral
Metadata
Title
Gene expression profiling in uveal melanoma: technical reliability and correlation of molecular class with pathologic characteristics
Authors
Kristen M. Plasseraud
Jeff K. Wilkinson
Kristen M. Oelschlager
Trisha M. Poteet
Robert W. Cook
John F. Stone
Federico A. Monzon
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2017
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-017-0650-3

Other articles of this Issue 1/2017

Diagnostic Pathology 1/2017 Go to the issue